Anzeige
Mehr »
Sonntag, 06.07.2025 - Börsentäglich über 12.000 News
LiquidLink startet Bitcoin Lightning- und XRP-ILP-Nodes - Aufbau des Rückgrats der tokenisierten Finanzwelt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
144 Leser
Artikel bewerten:
(0)

Isenolic Olive Leaf Extract Helps Halt Viral Lifecycle

MADRID, March 31, 2020 /PRNewswire/ -- Pharmactive launches its non-GMO olive leaf extract (Olea europaea L) marketed under the brand Isenolic, and grown under fully controlled conditions in the Mediterranean. The extract is standardized to =4% elenolic acid by HPLC. Elenolic acid has been heralded by scientific studies for its positive effect helping to prevent viral seasonal infections and promote immune health.

Isenolic Olive Leaf Extract Helps Halt Viral Lifecycle

Olive is the first botanical species mentioned in The Bible: "The fruit will be for food and the leaf for medicine" (Ezekiel 47:12). The use of olive leaves for medicinal purposes dates back to ancient Egypt, where they were considered a divine symbol as well as a popular remedy to combat fever. Similarly, Greek culture also used it to lower fever. Today, the olive leaf is attracting attention for its myriad functional benefits for the immune and cardiovascular systems.

"Elenolic acid is one of the most important olive secondary metabolites, and used by olive trees to naturally fight phytopathogens," explains Alberto Espinel, Head of R&D at Pharmactive. "It is the main bioactive component of olive trees contributing antimicrobial and antiviral functions of olive leaves, and - as determined by scientific studies that date back several decades - specifically targeting influenza A and B types, as well as para-influenza 1,2,3. A number of these studies demonstrate the compound's capabilities in preventing and reducing symptoms of viral and microbial infections, including shortening the duration of colds."

The benefits of elenolic acid are attributed to the compound's inherent multi-target mechanisms of action. Pharmactive's Isenolic elenolic acid, directly penetrates the cells and blocks the entry of specific viruses, effectively putting the brakes on their life cycle. It has also been shown to be a natural neuraminidase inhibitor, recommended by WHO for viral infection management. "Neuraminidase is a key enzyme that is present in the flu virus that acts to disassemble the virus from the host cell membrane, promoting its liberation to infect new cells. Isenolic prevents its liberation and subsequent proliferation," explains Espinel. A recent in vitro study demonstrated this potent inhibition effect of Isenolic on neuraminidase activity.

"Immune-boosting botanicals with roots in ancient or Traditional Medicine are factors that strongly resonate with consumers, who perceive them as natural and effective and respect their long history of safe use," adds Julia Diaz, Marketing Manager of Pharmactive. "Our Isenolic olive leaf extract is locally sourced from olive trees grown in fields in the Mediterranean and using an extraction process that is fully controlled and completely traceable, leveraging ancestral know-how in order to provide a final extract of the highest quality and purity."

Isenolic is water-soluble and can be delivered in a versatile range of supplement formats, including softgels, syrups, powders, and effervescent formulations. It can also be incorporated into food and beverage matrices. The ingredient is non-GMO, non-irradiated, doping free and both halal- and kosher-certified.

For more information, contact:

Company contact:

Press Contact:

Pharmactive Biotech Products, S.L.

NutriPR

Julia Diaz, Head of Marketing

Liat Simha

Tel: +34-91-112-38-48

Tel: +972-9-9742893

Email: marketing@pharmactive.eu

E-mail: liat@nutripr.com

Twitter: @Pharmactive_SP

Twitter: @NutriPR_

Web: www.pharmactive.eu

Website: www.nutripr.com

Photo: https://mma.prnewswire.com/media/1139665/Pharmactive_Olive_Leaf_Extract.jpg

© 2020 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.